Novo Nordisk (NVO) stock dropped on Monday despite the drugmaker reporting positive results for its GLP-1 medicine, Rybelsus.
CHMP recommends approval for XOANACYL, an oral therapy for use in the following therapeutic areas: Iron deficiency, chronic renal failure and ...
In response to a request from the European Medicines Agency (EMA) following the death of a 16-year-old patient in the U.S., ...
The European Medicines Agency (EMA) announced it is exploring improvements to the development and evaluation of biosimilar ...
Eli Lilly's Alzheimer's treatment is approved for use in the U.S. but the European Medicines Agency recommended against the ...
The EMA has recommended refusing marketing authorization for donanemab, a monoclonal antibody against amyloid beta, in the ...
SHANGHAI, China & JERSEY CITY, N.J.--(BUSINESS WIRE)--Shanghai Henlius Biotech, Inc. (2696.HK) and Organon (NYSE: OGN) today announced that the European Medicines Agency (EMA) has validated the ...
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) shared an update on Elevidys (delandistrogene moxeparvovec-rokl), the only approved ...
President Trump yesterday announced a baseline tariff of 10% on all imported products and higher rates on certain countries ...
Amid a raft of federal changes cutting funding and capacities at the Food and Drug Administration, investors are soon ...
After failing to pass muster with England’s drug reimbursement watchdog earlier this month, Eli Lilly’s Alzheimer’s disease ...
The Associated Press on MSN7d
European committee says Lilly Alzheimer’s drug shouldn’t get marketing approvalThe European Medicines Agency committee said the benefits of the new drug, Kisunla, did not outweigh the risks, and it ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback